We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Role of Krüppel-like factor 2 and protease-activated receptor-1 in vulnerable plaques of ApoE(-/-) mice and intervention with statin.
Canadian Journal of Cardiology 2013 August
BACKGROUND: Krüppel-like factor 2 (KLF2) and protease-activated receptor-1 (PAR-1) are 2 novel factors that play important roles in inflammation and coagulation, yet their relationship with vulnerable plaques and statin remains uncertain. The purpose of this study was to explore the expression of KLF2 and PAR-1 in vulnerable plaques of ApoE gene knockout (ApoE(-/-)) mice and the pharmaceutical effect of statin on the expression of KLF2 and PAR-1.
METHODS: ApoE(-/-) mice were randomized into an early-treatment group and a late-treatment group. Each group was randomized into 4 subgroups: normal diet control, high-fat diet control, high-dose statin, and low-dose statin. After 8 weeks of intervention with statin, the aortas were harvested to determine KLF2 and PAR-1 expression by semiquantitative reverse transcription-polymerase chain reaction, Western blotting, and immunohistochemical analyses. The relative area of plaque, the ratio of fibrous cap thickness to tunica intima/media thickness, and the vulnerability index of atherosclerotic plaques were calculated to evaluate plaque vulnerability.
RESULTS: KLF2 increased whereas PAR-1 decreased in vulnerable plaques at messenger RNA, protein, and histologic levels. Atorvastatin increased KLF2 and decreased PAR-1 expression.
CONCLUSIONS: Plaque vulnerability correlated negatively with KLF2 but positively with PAR-1. Upregulation of KLF2 and downregulation of PAR-1 could be direct or indirect effects of statin therapy.
METHODS: ApoE(-/-) mice were randomized into an early-treatment group and a late-treatment group. Each group was randomized into 4 subgroups: normal diet control, high-fat diet control, high-dose statin, and low-dose statin. After 8 weeks of intervention with statin, the aortas were harvested to determine KLF2 and PAR-1 expression by semiquantitative reverse transcription-polymerase chain reaction, Western blotting, and immunohistochemical analyses. The relative area of plaque, the ratio of fibrous cap thickness to tunica intima/media thickness, and the vulnerability index of atherosclerotic plaques were calculated to evaluate plaque vulnerability.
RESULTS: KLF2 increased whereas PAR-1 decreased in vulnerable plaques at messenger RNA, protein, and histologic levels. Atorvastatin increased KLF2 and decreased PAR-1 expression.
CONCLUSIONS: Plaque vulnerability correlated negatively with KLF2 but positively with PAR-1. Upregulation of KLF2 and downregulation of PAR-1 could be direct or indirect effects of statin therapy.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app